599 related articles for article (PubMed ID: 31285264)
1. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
2. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.
Hirano S; Udagawa O
Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus induces NRF2 degradation through a promyelocytic leukemia protein - ring finger protein 4 dependent pathway.
Komaravelli N; Ansar M; Garofalo RP; Casola A
Free Radic Biol Med; 2017 Dec; 113():494-504. PubMed ID: 29107745
[TBL] [Abstract][Full Text] [Related]
4. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
5. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
6. BCL11A is a SUMOylated protein and recruits SUMO-conjugation enzymes in its nuclear body.
Kuwata T; Nakamura T
Genes Cells; 2008 Sep; 13(9):931-40. PubMed ID: 18681895
[TBL] [Abstract][Full Text] [Related]
7. RNF111/Arkadia is a SUMO-targeted ubiquitin ligase that facilitates the DNA damage response.
Poulsen SL; Hansen RK; Wagner SA; van Cuijk L; van Belle GJ; Streicher W; Wikström M; Choudhary C; Houtsmuller AB; Marteijn JA; Bekker-Jensen S; Mailand N
J Cell Biol; 2013 Jun; 201(6):797-807. PubMed ID: 23751493
[TBL] [Abstract][Full Text] [Related]
8. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.
Han Y; Huang C; Sun X; Xiang B; Wang M; Yeh ET; Chen Y; Li H; Shi G; Cang H; Sun Y; Wang J; Wang W; Gao F; Yi J
J Biol Chem; 2010 Apr; 285(17):12906-15. PubMed ID: 20181954
[TBL] [Abstract][Full Text] [Related]
9. Quantitative SUMO proteomics reveals the modulation of several PML nuclear body associated proteins and an anti-senescence function of UBC9.
McManus FP; Bourdeau V; Acevedo M; Lopes-Paciencia S; Mignacca L; Lamoliatte F; Rojas Pino JW; Ferbeyre G; Thibault P
Sci Rep; 2018 May; 8(1):7754. PubMed ID: 29773808
[TBL] [Abstract][Full Text] [Related]
10. The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation.
Schilling EM; Scherer M; Reuter N; Schweininger J; Muller YA; Stamminger T
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903803
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
Bailey D; O'Hare P
Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
[TBL] [Abstract][Full Text] [Related]
12. Identification of RNF168 as a PML nuclear body regulator.
Shire K; Wong AI; Tatham MH; Anderson OF; Ripsman D; Gulstene S; Moffat J; Hay RT; Frappier L
J Cell Sci; 2016 Feb; 129(3):580-91. PubMed ID: 26675234
[TBL] [Abstract][Full Text] [Related]
13. The ubiquitin-like modifier FAT10 interferes with SUMO activation.
Aichem A; Sailer C; Ryu S; Catone N; Stankovic-Valentin N; Schmidtke G; Melchior F; Stengel F; Groettrup M
Nat Commun; 2019 Oct; 10(1):4452. PubMed ID: 31575873
[TBL] [Abstract][Full Text] [Related]
14. SUMOylation promotes PML degradation during encephalomyocarditis virus infection.
El McHichi B; Regad T; Maroui MA; Rodriguez MS; Aminev A; Gerbaud S; Escriou N; Dianoux L; Chelbi-Alix MK
J Virol; 2010 Nov; 84(22):11634-45. PubMed ID: 20826694
[TBL] [Abstract][Full Text] [Related]
15. The important roles of protein SUMOylation in the occurrence and development of leukemia and clinical implications.
Zhao B; Zhang Z; Chen X; Shen Y; Qin Y; Yang X; Xing Z; Zhang S; Long X; Zhang Y; An S; Wu H; Qi Y
J Cell Physiol; 2021 May; 236(5):3466-3480. PubMed ID: 33151565
[TBL] [Abstract][Full Text] [Related]
16. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.
Liang YC; Lee CC; Yao YL; Lai CC; Schmitz ML; Yang WM
Sci Rep; 2016 May; 6():26509. PubMed ID: 27211601
[TBL] [Abstract][Full Text] [Related]
17. Arkadia/RNF111 is a SUMO-targeted ubiquitin ligase with preference for substrates marked with SUMO1-capped SUMO2/3 chain.
Sriramachandran AM; Meyer-Teschendorf K; Pabst S; Ulrich HD; Gehring NH; Hofmann K; Praefcke GJK; Dohmen RJ
Nat Commun; 2019 Aug; 10(1):3678. PubMed ID: 31417085
[TBL] [Abstract][Full Text] [Related]
18. N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.
Sharma P; Murillas R; Zhang H; Kuehn MR
J Cell Sci; 2010 Apr; 123(Pt 8):1227-34. PubMed ID: 20233849
[TBL] [Abstract][Full Text] [Related]
19. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
Fasci D; Anania VG; Lill JR; Salvesen GS
Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
[TBL] [Abstract][Full Text] [Related]
20. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
